Andrew Cheng, President en CEO van Akero Therapeutics, Inc. (NASDAQ:AKRO), een biotechnologiebedrijf dat volgens InvestingPro -analyse momenteel tekenen van onderwaardering vertoont, heeft op 11 augus ...

Jonathan Young, Chief Operating Officer van Akero Therapeutics, Inc. (NASDAQ:AKRO), heeft op 12 augustus 2025 in meerdere transacties 12.500 gewone aandelen verkocht. De verkopen werden uitgevoerd teg ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic ...

Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Find out why AKRO stock is a Buy.

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic ...

Akero Therapeutics is dedicated to collaborating closely with the FDA and anticipates finalizing the design for a third Phase 3 study, SYNCHRONY Outcomes, after receiving the Phase 2b SYMMETRY ...

--Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) is up 71.75% year-to-date. Overall AKRO ranks 4th on our list of the biotech stocks that are skyrocketing so far in 2025.

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH.